Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 9;13:868809. doi: 10.3389/fimmu.2022.868809

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Yuan, Xie, Song, Li, Li, Hu, Zang, Cheng, Lu, Huang, Fan, Rong, Sun and Chen

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Validation of the high stiffness signature in TCGA-LIHC and GSE109211 datasets. (A) Boxplots of cell infiltration, as calculated by the Microenvironment Cell Populations-counter (MCP-counter), among tumors with high and low stiffness from The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) cohort. (B, C) Heatmap (B) and volcano plot (C) comparing differences in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways between tumors with high and low stiffness in the TCGA-LIHC cohort. (D–G) Boxplots of tumor purity (D), intratumoral heterogeneity (ITH) (E), neoantigen (F), and tumor mutation burden (G) in the 4 studied histone modification patterns of the TCGA-LIHC cohort. (H) Kaplan-Meier curves of overall survival in the TCGA-LIHC cohort according to tumor stiffness. (I) Violin plot of the estimated IC50 value of sorafenib and sunitinib calculated based on the Genomics of Drug Sensitivity in Cancer database among tumors with high or low stiffness in the TCGA-LIHC cohort. (J) Boxplots of cell infiltration levels calculated by the MCP-counter among tumors with high and low stiffness in the GSE109211 cohort. (K, L) Heatmap (K) and volcano plot (L) comparing differences in KEGG pathways between tumors with high and low stiffness in the GSE109211 cohort. (M) Bar charts summarizing the proportions of patients with different sorafenib responses across different tumor stiffness groups in the GSE109211 cohort. (N) Receiver operating characteristic curves of treatment response predictions of sorafenib according to the tumor stiffness signature in the GSE109211 cohort. NS means not-siginificant (without statistical difference); *** means p value < 0.001; **** means p value < 0.0001.